Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy ...
Pharmaceutical Technology on MSN
BMS reports flat revenue growth for full-year 2025
The company projects 2026 revenues between $46.0bn and $47.5bn, with non-GAAP EPS ranging from $6.05 to $6.35.
The latest OXB agreement will help advance the company’s CAR-T therapies and provide a “reliable, scalable manufacturing ...
Ahead of the readouts, BMS and J&J have started an educational push called “Change the Target. Change What’s Possible,” they announced Tuesday. The campaign is designed to inform clinicians who manage ...
Bristol Myers Squibb (BMS) is confident pivotal readouts from its core pipeline will drive profits towards 2030 despite looming patent expiries for revenue leaders Opdivo and Eliquis, says CEO ...
BMY Q4 2025 earnings call recap: growth portfolio momentum, pipeline catalysts, 2026 guidance, and Eliquis LOE risks.
Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...
There’s been no festive respite for Bristol Myers Squibb’s M&A team as the Big Pharma follows up its acquisition of Karuna Therapeutics with the announcement straight after Christmas that it's also ...
Huzhou FFD Power will localize BMS, EMS, and C&I BESS cabinet production in Europe; initial cabinet platforms: 261 ...
Sunny Deol's awaaz is roaring on the 3rd Sunday with Border 2 all set for a huge box office jump - BMS trends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results